The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Self-citation
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Mechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Pradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis
Marra, F., Gastaldelli, A., Svegliati Baroni, G., Tell, G., & Tiribelli, C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.003 · Cited by 425
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 379
CB 1 and CB 2 Receptor Pharmacology
Howlett, A. C., & Abood, M. E. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.03.007 · Cited by 375
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Self-citationThe Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Jeong, W.-I., Osei-Hyiaman, D., Park, O., Liu, J., Bátkai, S., Mukhopadhyay, P., Horiguchi, N., Harvey-White, J., Marsicano, G., Lutz, B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.007 · Cited by 310
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Popov, Y., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 296
Endocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
Macrophage autophagy protects against liver fibrosis in mice
Lodder, J., Denaës, T., Chobert, M.-N., Wan, J., El-Benna, J., Pawlotsky, J.-M., Lotersztajn, S., & Teixeira-Clerc, F. (2015) · Autophagy · doi:10.1080/15548627.2015.1058473 · Cited by 266
Self-citationNon-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256
Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver
Hegde, P., Weiss, E., Paradis, V., Wan, J., Mabire, M., Sukriti, S., Rautou, P.-E., Albuquerque, M., Picq, O., Gupta, A. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04450-y · Cited by 232
Self-citationXiang, D.-M., Sun, W., Ning, B.-F., Zhou, T.-F., Li, X.-F., Zhong, W., Cheng, Z., Xia, M.-Y., Wang, X., Deng, X., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313392 · Cited by 229
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
Pacher, P., & Haskó, G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707582 · Cited by 217
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis
Mallat, A., & Lotersztajn, S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00230.2013 · Cited by 211
Self-citationPathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Self-citationInhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver
Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., Ribeiro-Parenti, L., Le Gall, M., Lettéron, P., Pilard, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316137 · Cited by 91
Self-citationReview article: the reversibility of cirrhosis
Sohrabpour, A. A., Mohamadnejad, M., & Malekzadeh, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12044 · Cited by 80
Wan, J., Weiss, E., Ben Mkaddem, S., Mabire, M., Choinier, P.-M., Picq, O., Thibault-Sogorb, T., Hegde, P., Pishvaie, D., Bens, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8523 · Cited by 77
Self-citationInvolvement of the endocannabinoid system in periodontal healing
Kozono, S., Matsuyama, T., Biwasa, K. K., Kawahara, K.-I., Nakajima, Y., Yoshimoto, T., Yonamine, Y., Kadomatsu, H., Tancharoen, S., Hashiguchi, T., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.080 · Cited by 62
Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts
Garcia-Gonzalez, E., Selvi, E., Balistreri, E., Lorenzini, S., Maggio, R., Natale, M.-R., Capecchi, P.-L., Lazzerini, P.-E., Bardelli, M., Laghi-Pasini, F., et al. (2009) · Rheumatology · doi:10.1093/rheumatology/kep189 · Cited by 63
New trends for the medical treatment of endometriosis
Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60
Fu, Q., Zheng, Y., Dong, X., Wang, L., & Jiang, C. G. (2017) · Oncotarget · doi:10.18632/oncotarget.21975 · Cited by 40
Role of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17
Metadata
- Authors
- Teixeira-Clerc, F., Julien, B., Grenard, P., Van Nhieu, J. T., Deveaux, V., Li, L., Serriere-Lanneau, V., Ledent, C., Mallat, A., & Lotersztajn, S.
- Venue
- Nature Medicine
- Published
- 2006-05-21
- Volume
- 12
- Issue
- 6
- Pages
- 671-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1967973854
- Cited by
- 528
- References
- 2
- FWCI
- 35.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.